Publications by authors named "T Lizee"
Article Synopsis
- Salvage and adjuvant radiotherapy are effective for prostate cancer, but 30%-40% of patients experience disease progression, prompting a study to analyze recurrence patterns after treatment.
- In a study of 935 prostate cancer patients, 205 developed biochemical failure, and 166 were assessed through imaging, identifying 244 failure sites categorized as local, locoregional, or metastatic.
- The findings revealed that 52% of patients had metastatic disease after treatment, particularly those treated at the prostate and pelvic lymph nodes, highlighting the need for personalized radiation therapy based on imaging results.
Systematic review for the treatment of high-risk prostate cancer (HR-PCa, D'Amico classification risk system) with external body radiation therapy (EBRT)+brachytherapy-boost (BT-boost) or with EBRT+stereotactic body RT-boost (SBRT-boost). In March 2020, 391 English citations on PubMed matched with search terms "high risk prostate cancer boost". Respectively 9 and 48 prospective and retrospective studies were on BT-boost and 7 retrospective studies were on SBRT-boost.
View Article and Find Full Text PDFRadiation-induced myelopathy is a devastating late effect of radiotherapy. Fortunately, this late effect is exceptional. The clinical presentation of radiation myelopathy is aspecific, typically occurring between 6 to 24 months after radiotherapy, and radiation-induced myelopathy remains a diagnosis of exclusion.
View Article and Find Full Text PDFSynchronous metastatic breast cancer accounts for 5 to 6% of all breast cancers in Western countries, which corresponds to nearly 2500 new cases per year in France. Irradiation of the primary tumour in cases of metastatic disease at diagnosis was historically reserved for palliative indications. However, progress in systemic treatments, a better understanding of the biological basis of metastatic dissemination, the genesis of the concept of oligometastatic disease and ablative treatments directed towards metastases are revolutionizing the management of patients with de novo stage IV breast cancer.
View Article and Find Full Text PDFArticle Synopsis
- * Lobectomy surgery is the standard treatment for T1-T2 localized non-small cell lung carcinoma, while segmentectomy may be considered for patients with compromised respiratory health.
- * For patients who are inoperable or have poor lung function, stereotactic radiotherapy offers a high local control rate (85-95%) over 3-5 years, and research is ongoing to assess factors that influence these outcomes.